40. Van Cutsem E, Findlay M, Osterwalder B et al. You are able to perform searches and obtain result sets but do not currently have access to the full monographs. Fine RL, Gulati AP, Krantz BA, et al.

43. Bevacizumab in combinations with capecitabine is not recommended within its marketing authorisation for the first-line treatment of metastatic breast cancer, that is, when treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate, or when taxanes or anthracyclines have been used as part of adjuvant treatment in the previous 12 months.

Allegra C, Sargent DJ. Oral versus intravenous fluoropyrimidines for advanced colorectal cancer: by either route, it's all the same. 24.

<< /BM /Normal AHFS final determination of medical acceptance: Off-label use of capecitabine in combination with oxaliplatin for the adjuvant treatment of stage III colon cancer. /Height 609 Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC): efficacy and safety results. 1987:18-24.14. Capecitabine is an anti-cancer drug, a prodrug of doxifluridine, metabolized to 5-fluorouracil at the tumor site.
Roche Laboratories. Packaging Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. Pinedo HM, Peters GFJ. 6 0 obj
11. Van Cutsem E, Twelves C, Cassidy J et al.

9. Data on file. Antitumor efficacy of capecitabine against fluorouracil-sensitive and -resistant tumors. 10004. 10. ACH-CAPECITABINE is also indicated for the first-line treatment of patients with metastatic colorectal cancer. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. Sandoz Capecitabine (capecitabine) is indicated for: Colorectal Cancer Monotherapy Sandoz Capecitabine (capecitabine) is indicated for the adjuvant treatment of patients with stage III (Dukes’ stage C) colon cancer. /Width 2040 10002. 15. Schmoll HJ, Tabernero J, Maroun J et al. 21. Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. Used alone as adjuvant therapy following the complete resection of primary tumor in patients with stage III (Dukes’ C) colon cancer when treatment with fluoropyrimidine therapy alone is preferred.1 40 41 47 48 Combined therapy with IV oxaliplatin† is a reasonable choice (accepted, treatment option) as adjuvant t… Roche Laboratories. Clinical reference 111-005.25. /BitsPerComponent 1 /SMask /None /Length 8068 Benedetti F. Dear doctor letter: Important prescribing information: potential Xeloda interaction with coumarin derivatives. From: PDQ. Physician data query (database).

Colorectal Cancer Monotherapy  XELODA (capecitabine) is indicated for the adjuvant treatment of patients with stage III (Dukes’ stage C) colon cancer. National Comprehensive Cancer Network (NCCN). Packaging Unit quantity: 150 mg. Subject to change. 4 0 obj )Prodrug; has little pharmacologic activity until it is converted to fluorouracil, an antimetabolite.Converted to fluorouracil by enzymes that are expressed at higher concentrations in many tumors than in adjacent normal tissues or plasma; high tumor concentrations of the active drug may be achieved with less systemic toxicity.Fluorouracil is metabolized in both normal and tumor cells to 5-fluoro-2′-deoxyuridine 5′-monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP).Active in xenograft tumors that are resistant to fluorouracil indicating incomplete cross-resistance between the drugs.Importance of informing clinician of any known deficiency in DPD activity.Importance of discontinuing the drug and contacting clinician if stool output increases by 4–6 stools or more daily or if nocturnal stools or severe bloody diarrhea with severe abdominal pain and fever occurs.Importance of discontinuing the drug and contacting clinician if grade 2 or greater dehydration occurs.Importance of discontinuing the drug and contacting clinician if 2–5 or more episodes of vomiting occur in a 24-hour period.Importance of discontinuing the drug and contacting clinician if nausea resulting in a substantial decrease in food intake occurs.Importance of discontinuing the drug and contacting clinician if pain, redness, swelling, or sores in mouth occur.Importance of discontinuing the drug and contacting clinician if pain and swelling or redness of hands or feet that prevents normal activity occur.Importance of notifying clinician if fever (≥100.5°F) or other signs of infection occur.Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses.Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed; necessity for clinicians to advise women to avoid pregnancy during therapy and to advise pregnant women of risk to the fetus.Importance of informing patients of other important precautionary information.2. Data on file. Published November 9, 2016The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records.

5th ed. Twelves C, Glynne-Jones R, Cassidy J et al. 47.

45.

Clinical reference 111-013.28. Mayer RJ. Roche Laboratories, Nutley, NJ: Personal communication.27. Cao S, Lu K, Ishitsuka H et al. 3.

Oncologic Drugs Advisory Committee Meeting. MECHANISM OF ACTION: Capecitabine is a prodrug that is selectively tumour -activated to its cytotoxic moiety, fluorouracil, by thymidine phosphorylase. Version 2.2016.42.